N-3 Polyunsaturated Fatty Acids Enriched Chicken Meet and Cardiovascular Function

February 2, 2023 updated by: Ines Drenjancevic, Josip Juraj Strossmayer University of Osijek

Effects of N-3 Polyunsaturated Fatty Acids Enriched Chicken Meet on Cardiovascular Function

Evidence from multiple experimental, epidemiological, and clinical studies indicate that n-3 polyunsaturated fatty acids (n-3 PUFAs) may exert their cardiovascular (CV) protective effect, at least in part, by improving vascular endothelium-dependent function. Previously, the investigators demonstrated the significant beneficiary effect of consumption of n-3 PUFA-enriched hen eggs on microvascular endothelium-dependent reactivity, even in young healthy individuals.

The hypothesis of this research is that the consumption of n-3 PUFAs in the form of functionally enriched chicken meet has a beneficial effect on vascular reactivity measured in different vascular beds, and the lipid profile with a positive effect on the reduction of oxidative stress and inflammatory response in healthy sedentary individuals.

The main goal of this study is to investigate the influence of n-3 PUFAs functionally enriched chicken meet on vascular and endothelial function in a population of healthy young subjects and active athletes.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Osijek, Croatia, 31000
        • Recruiting
        • Scientific Center of Excellence for Personalized Health Care, Josip Juraj Strossayer University of Osijek
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 39 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • young healthy sedentary individuals - did not perform regular physical activities for at least 12 months before conducting the study
  • young healthy active athletes - have a minimum of 5 training sessions per week (mainly endurance training) for at least 12 months prior to conducting the study

Exclusion Criteria:

  • smoking
  • hypertension
  • coronary disease
  • diabetes
  • hyperlipidemia
  • kidney damage
  • cerebrovascular and peripheral artery diseases
  • and any other disease that could have an impact on vascular and endothelial function

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: n-3 PUFA
Intake of n-3 PUFAs enriched chicken meet for three weeks
Intake of n-3 PUFAs enriched chicken meet for three weeks.
EXPERIMENTAL: Control
Intake of regular chicken meet for three weeks
Intake of regular chicken meet for three weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Microvascular endothelial function
Time Frame: 3 weeks
Cutaneous microvascular blood flow will be measured by Laser Doppler Flowmetry in response to vascular occlusion (post occlusive reactive hyperaemia - PORH), in response to iontophoresis of acetylcholine (ACh) and local thermal hyperemia (LTH).
3 weeks
Macrovascular endothelial function
Time Frame: 3 weeks
Measurement of flow mediated dilation (FMD) of brachial artery using ultrasound.
3 weeks
Cerebrovascular reactivity
Time Frame: 3 weeks
Measurement of cerebrovascular blood flow using transcranial color Doppler (TCD).
3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lipid profile
Time Frame: 3 weeks
Measurement of plasma cholesterol, HDL cholesterol, LDL cholesterol and triglycerides level.
3 weeks
Oxidative stress status
Time Frame: 3 weeks
Measurement of Thiobarbituric Acid Reactive Substances (TBARS).
3 weeks
Systemic hemodynamics
Time Frame: 3 weeks
Non-invasive assessment of systemic hemodynamics using impedance cardiography (CardioScreen 2000) - SV Stroke Volume (mL), CO Cardiac Output (L/min) and SVRI Systemic Vascular Resistance Index (dyn.s.cm-5 m2).
3 weeks
Serum Pro- and Anti-Inflammatory Cytokines, Chemokines, Growth Factors and Soluble Cell Adhesion Molecules Protein Concentration
Time Frame: 3 weeks
Measurement of serum protein concentration (pg/mL) of various pro- and anti-inflammatory cytokines, chemokines, growth factors and soluble cell adhesion molecules by kits and panels for multiplex protein quantitation using the Luminex 200 instrument platform.
3 weeks
Body composition
Time Frame: 3 weeks
Body composition and body fluid status measurement by a four-terminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically derived formulas (the original manufacturer's software) will be used to calculate the estimated Fat Free Mass (FFM kg) and Fat (Fat Mass kg).
3 weeks
Body fluid status
Time Frame: 3 weeks
Body fluid status measurement by a four-terminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically derived formulas (the original manufacturer's software) will be used to calculate the estimated Total Body Water (TBW L), Extracellular Water (ECW L), Intracellular Water (ICW L), Plasma Fluid (PF L) and Interstitial Fluid (IF L).
3 weeks
Oxidative stress status
Time Frame: 3 weeks
Measurement of Ferric-Reducing Ability of Plasma (FRAP).
3 weeks
Oxidative stress status
Time Frame: 3 weeks
Measurement of enzyme activity assay of glutathione peroxidase (GPx).
3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 1, 2022

Primary Completion (ANTICIPATED)

December 31, 2023

Study Completion (ANTICIPATED)

June 30, 2024

Study Registration Dates

First Submitted

January 24, 2023

First Submitted That Met QC Criteria

February 2, 2023

First Posted (ACTUAL)

February 13, 2023

Study Record Updates

Last Update Posted (ACTUAL)

February 13, 2023

Last Update Submitted That Met QC Criteria

February 2, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on n-3 Polyunsaturated Fatty Acids

Clinical Trials on N-3 PUFAs Chicken Meet

3
Subscribe